Teva Pharmaceuticals settles $450M for Anti-Kickback Statute violations and price-fixing.

Teva Pharmaceuticals will pay $450 million to settle allegations of violating the Anti-Kickback Statute. From 2006 to 2017, the company allegedly covered Medicare patients' copays for its multiple sclerosis drug Copaxone while raising its price. Additionally, Teva admitted to price-fixing with other generic manufacturers for several drugs. The settlement includes a $225 million criminal penalty and resolves multiple kickback schemes.

October 11, 2024
6 Articles